help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoppet, M.
Right arrow Articles by Hofbauer, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoppet, M.
Right arrow Articles by Hofbauer, L. C.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 3 1024-1028
Copyright © 2003 by The Endocrine Society

Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease

Michael Schoppet, Alexander M. Sattler, Juergen R. Schaefer, Matthias Herzum, Bernhard Maisch and Lorenz C. Hofbauer

Departments of Internal Medicine and Cardiology (M.S., A.M.S., J.R.S., M.H., B.M.) and Gastroenterology, Endocrinology, and Metabolism (L.C.H.), Philipps University, Baldingerstrasse, D-35033 Marburg, Germany

Address all correspondence and requests for reprints to: Lorenz C. Hofbauer, M.D., Division of Gastroenterology, Endocrinology, and Metabolism, Department of Medicine, Philipps University, Baldingerstrasse, D-35033 Marburg, Germany. E-mail: hofbauer{at}post.med.unimarburg.de.

Osteoprotegerin (OPG) regulates osteoclast and immune functions and appears to represent a protective factor for the vascular system. However, the role of OPG in human atherosclerosis has not been evaluated. In this study, we assessed OPG serum levels in 522 age-matched men who, on the basis of coronary angiography, had either absence of coronary artery disease (CAD) or presence of single-vessel disease, double-vessel disease, or severe triple-vessel disease. OPG serum levels were positively correlated with age (r = 0.28; P < 0.001) and were higher in men with diabetes mellitus (P < 0.01). OPG serum levels in men without CAD were 5.4 ± 2.0 pmol/liter, compared with 6.1 ± 2.1 pmol/liter in single-vessel disease (P < 0.005), 5.9 ± 2.4 in double-vessel disease (P < 0.05), and 6.3 ± 2.3 pmol/liter in triple-vessel disease (P < 0.001). Moreover, OPG serum levels were positively correlated with the severity of CAD as determined by a CAD scoring system (r = 0.17; P < 0.01). In conclusion, our data underline that OPG serum levels are associated with the severity of CAD and are increased in elderly men and patients with diabetes mellitus. We conclude that increased OPG serum levels may reflect advanced cardiovascular disease in men.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ho 1875/2-1) and from the Deutsche Krebshilfe (10-1697-Ho1) to L.C.H. and the Kempkes-Stiftung to J.R.S.

M.S. and A.M.S. contributed equally to this work.

Abbreviations: CAD, Coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-{kappa}B ligand.




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
M. Gossl, U. I. Modder, E. J. Atkinson, A. Lerman, and S. Khosla
Osteocalcin Expression by Circulating Endothelial Progenitor Cells in Patients With Coronary Atherosclerosis
J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1314 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
H. F Escobar-Morreale, J. I Botella-Carretero, M. A. Martinez-Garcia, M. Luque-Ramirez, F. Alvarez-Blasco, and J. L S. Millan
Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome
Eur. J. Endocrinol., September 1, 2008; 159(3): 225 - 232.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. L. Demer and Y. Tintut
Vascular Calcification: Pathobiology of a Multifaceted Disease
Circulation, June 3, 2008; 117(22): 2938 - 2948.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M.-H. Gannage-Yared, C. Yaghi, B. Habre, S. Khalife, R. Noun, M. Germanos-Haddad, and V. Trak-Smayra
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study
Eur. J. Endocrinol., March 1, 2008; 158(3): 353 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Omland, T. Ueland, A. M. Jansson, A. Persson, T. Karlsson, C. Smith, J. Herlitz, P. Aukrust, M. Hartford, and K. Caidahl
Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes.
J. Am. Coll. Cardiol., February 12, 2008; 51(6): 627 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
M. K. Shea, S. L. Booth, J. M. Massaro, P. F. Jacques, R. B. D'Agostino Sr, B. Dawson-Hughes, J. M. Ordovas, C. J. O'Donnell, S. Kathiresan, J. F. Keaney Jr, et al.
Vitamin K and Vitamin D Status: Associations with Inflammatory Markers in the Framingham Offspring Study
Am. J. Epidemiol., February 1, 2008; 167(3): 313 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Nellemann, L. C. Gormsen, J. Dollerup, O. Schmitz, C. E. Mogensen, L. M. Rasmussen, and S. Nielsen
Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria
Diabetes Care, December 1, 2007; 30(12): 3122 - 3124.
[Full Text] [PDF]

Home page
 CirculationHome page
S. Kiechl, G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit
Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease
Circulation, July 24, 2007; 116(4): 385 - 391.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Blood, July 15, 2007; 110(2): 536 - 543.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
T. Omland, M. H. Drazner, T. Ueland, M. Abedin, S. A. Murphy, P. Aukrust, and J. A. de Lemos
Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function
Hypertension, June 1, 2007; 49(6): 1392 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Stompor, M. Krzanowski, B. Kusnierz-Cabala, M. Dubiel, M. Stompor, T. Grodzicki, and W. Sulowicz
Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3605 - 3606.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, and G. Zauli
An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction
Am. J. Pathol., December 1, 2006; 169(6): 2236 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Y. Shin, Y. G. Shin, and C. H. Chung
Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 Diabetes
Diabetes Care, July 1, 2006; 29(7): 1664 - 1666.
[Full Text] [PDF]

Home page
 DiabetesHome page
G.-d. Xiang, L. Xu, L.-s. Zhao, L. Yue, and J. Hou
The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.
Diabetes, July 1, 2006; 55(7): 2126 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder
The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic Subjects
J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1850 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
W. J. Sandberg, A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A.-K. L. Robertson, F. Muller, A. G. Semb, H. Scholz, et al.
Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 857 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients
Eur. J. Endocrinol., January 1, 2006; 154(1): 75 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Morena, N. Terrier, I. Jaussent, H. Leray-Moragues, L. Chalabi, J.-P. Rivory, F. Maurice, C. Delcourt, J.-P. Cristol, B. Canaud, et al.
Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 262 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
F. Galluzzi, S. Stagi, R. Salti, S. Toni, E. Piscitelli, G. Simonini, F. Falcini, and F. Chiarelli
Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status
Eur. J. Endocrinol., December 1, 2005; 153(6): 879 - 885.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]

Home page
 INT J LOW EXTREM WOUNDSHome page
W. J. Jeffcoate
Abnormalities of Vasomotor Regulation in the Pathogenesis of the Acute Charcot Foot of Diabetes Mellitus
International Journal of Lower Extremity Wounds, September 1, 2005; 4(3): 133 - 137.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
A. Avignon, A. Sultan, C. Piot, S. Elaerts, J. P. Cristol, and A. M. Dupuy
Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients
Diabetes Care, September 1, 2005; 28(9): 2176 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. Ueland, A. Yndestad, E. Oie, G. Florholmen, B. Halvorsen, S. S. Froland, S. Simonsen, G. Christensen, L. Gullestad, and P. Aukrust
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure
Circulation, May 17, 2005; 111(19): 2461 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, A. M. Djanani, D. H. Sturn, J. R. Patsch, and C. J. Wiedermann
Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I. B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, et al.
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1970 - 1976.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. L. Demer and M. Abedin
Skeleton key to vascular disease
J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1977 - 1979.
[Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. Jorgensen, O. Joakimsen, G. K. Rosvold Berntsen, I. Heuch, and B. K. Jacobsen
Low Bone Mineral Density Is Related to Echogenic Carotid Artery Plaques: A Population-based Study
Am. J. Epidemiol., September 15, 2004; 160(6): 549 - 556.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Rubin and S. J. Silverberg
Vascular Calcification and Osteoporosis--The Nature of the Nexus
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4243 - 4245.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Endocr. Rev., August 1, 2004; 25(4): 629 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Soufi, M. Schoppet, A. M. Sattler, M. Herzum, B. Maisch, L. C. Hofbauer, and J. R. Schaefer
Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3764 - 3768.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schoppet, N. Al-Fakhri, F. E. Franke, N. Katz, P. J. Barth, B. Maisch, K. T. Preissner, and L. C. Hofbauer
Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Monckeberg's Sclerosis and Atherosclerosis
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4104 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. C. Hofbauer and M. Schoppet
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
JAMA, July 28, 2004; 292(4): 490 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Abedin, Y. Tintut, and L. L. Demer
Vascular Calcification: Mechanisms and Clinical Ramifications
Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1161 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, W. Poewe, and J. Willeit
Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease
Circulation, May 11, 2004; 109(18): 2175 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Schoppet, J. R. Schaefer, L. C. Hofbauer, S. Jono, K. Mori, Y. Nishizawa, A. Shioi, T. Miki, Y. Ikari, and K. Hara
Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men * Response
Circulation, March 25, 2003; 107 (11): e76 - e76.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society